Humacyte, Inc. — Director's Dealing 2022

Dec 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-12-13

Reporting Person: Niklason Laura E (Director, President, CEO and Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-13	Common Stock	S	330000	$2.84	Disposed	18600004	Indirect
2022-12-14	Common Stock	S	276304	$2.76	Disposed	18323700	Indirect
2022-12-15	Common Stock	S	93426	$2.63	Disposed	18230274	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1160240	Direct
Common Stock	510161	Indirect

Footnotes

F1: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

F2: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.